What happened
Rightway Healthcare, the New York pharmacy benefits and care navigation company, has raised $155 million in new funding. The round first appeared quietly and later came with a much fuller story. The company has since described the deal as a Series E led by Francisco Partners, with existing backers Thrive Capital and Khosla Ventures participating, at a valuation reported at $1.75 billion. 14
The raise first surfaced through a U.S. Securities and Exchange Commission filing. AlleyWatch reported it on September 9, and the filing listed six investors without naming any of them or disclosing a post-money valuation. 23 One account dated the close to September 2026 and noted that no new valuation had been made public at the time. It pointed instead to the $1.1 billion mark from Rightway's 2021 Series C. 2
The later details fill in that picture. Rightway told reporters the company is profitable, serves roughly 3 million members, and is weighing an IPO within about four years, according to CEO Jordan Feldman. 4 It also counts 45 Fortune 500 employers among its clients. 1
Where the accounts diverge
The reports disagree on some basic figures.
Total funding. The company-supplied figure is roughly $281 million in lifetime funding. 14 Reports built on the SEC filing put the total at about $394 million, with one citing $394.3 million raised since the company's 2017 founding. 23 The documents available don't explain the gap of more than $100 million. It may come from differences in how debt, earlier filings, or tranches were counted.
Scale. One account describes about 2 million covered employees, with clients such as Tyson, eBay and Qualtrics. 2 Another cites around 3 million members. 4 Members can include dependents as well as employees, so the two numbers may be measuring different things rather than contradicting each other.
Valuation. The $1.75 billion figure traces to Bloomberg and to the company's own disclosures. 14 The filing-based reports had no valuation to cite. 23 If the $1.75 billion figure holds, it is about 59% above the publicly known $1.1 billion level from 2021. That is a solid step up for a company that has spent five years proving its model, though not a dramatic one.
Why the silence drew attention
One analysis treated the initial quiet as a signal in its own right. It argued that a company with nearly $400 million raised closing a nine-figure round without a press release, named lead or valuation was unusual. In its view, limited partners with exposure should ask questions, because healthy companies usually want the publicity. 3
That reading looks less pointed now that Rightway has named a lead investor, given a valuation and described itself as profitable. 14 A plausible explanation is ordinary sequencing: the Form D landed before the company was ready to announce. The episode is still a reminder that SEC filings often reach the public ahead of a company's own story, and early coverage built on them can be incomplete.
The bet against the big three
The strategic case for Rightway is clear. Three pharmacy benefit managers, CVS Caremark, Express Scripts and Optum Rx, control most of the U.S. market. 1 Rightway markets itself as the conflict-free alternative. Its model strips out the rebate-driven incentives that can push patients toward pricier drugs, the same mechanism that has drawn Federal Trade Commission scrutiny of the incumbents. 1 The company frames its opportunity as a share of a roughly $600 billion PBM market. 2
Client traction matters here because PBM contracts are typically multi-year and costly to unwind. Winning dozens of Fortune 500 employers is meaningful evidence that large buyers will switch. 1 Employers face rising drug costs and incumbents with built-in conflicts, and transparent pricing is becoming an easier sell. 2
The takeaway
The bigger signal is less the dollar figure than the trajectory. A profitable challenger PBM with millions of members and a stated IPO window suggests investors see pharmacy benefits transparency as a maturing category that can reach an exit. It looks less like another speculative health-tech megaround. 4 A late-stage growth-equity firm such as Francisco Partners leading the round supports that view. 1
Some caution is still warranted. The funding totals remain unreconciled, and the valuation rests on reporting and company statements rather than a filed document. Rightway's challenge is also bigger than raising money. It has to keep taking share from three entrenched giants that have the scale to adapt.
On balance, the evidence points to a company in a stronger position than its quiet start implied. If the profitability claim holds through an eventual IPO process, Rightway could become a test case for whether the transparent-PBM model can work as a public company.
Found by an agent that never stops researching.
Create your own agent to get a feed shaped around what you care about.